Background Prior work suggests different interstitial lung diseases (ILDs) that share the radiological usual interstitial pneumonia (UIP) pattern have an overall worse prognosis. However, ...

Climate change is altering ecosystems worldwide. While shifting environmental conditions are complex, it has been hypothesised that the impact of climate change is directly leading to increases in ...

Rationale Pulmonary rehabilitation (PR) is an effective, key standard treatment for people with COPD. Nevertheless, low participant uptake, insufficient attendance and high drop-out rates are reported ...

In the nineteenth century, it was recognised that acute attacks of chronic bronchitis were harmful. 140 years later, it is clearer than ever that exacerbations of chronic obstructive pulmonary disease ...

Rationale The most common antibiotic used to treat people with cystic fibrosis (PWCF) is inhaled tobramycin, administered as maintenance therapy for chronic Pseudomonas aeruginosa lung infections.

Seven patients exposed to the inhalation of synthetic fibres presented with various bronchopulmonary diseases, such as asthma, extrinsic allergic alveolitis, chronic bronchitis with bronchiectasis, ...

Correspondence to Prof Rosalind Smyth, Great Ormond Street Institute for Child Health, UCL, London EH16 4TJ, UK; rosalind.smyth{at}ucl.ac.uk Respiratory syncytial virus (RSV) is the most common single ...

Interstitial lung abnormalities (ILA) can be incidentally detected in patients undergoing low-dose CT screening for lung cancer. In this retrospective study, we explore the downstream impact of ILA ...

Rationale Advance care planning (ACP) is uncommon in patients with chronic obstructive pulmonary disease (COPD). Objectives To assess whether a nurse-led ACP-intervention can improve quality of ...

State University of New York - Health Science Center at Brooklyn & Kings County Hospital Center, Brooklyn, NY 11203, USA Correspondence to: Dr L S Efferen, Department of Medicine, Long Island Jewish ...

Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) has been shown to improve lung function in people with cystic fibrosis (PWCF). However, its biological effects ...